Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation.

Atherosclerosis Coronary artery disease Gut microbiota Short-chain fatty acids Trimethylamine N-oxide

Journal

Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427

Informations de publication

Date de publication:
29 12 2022
Historique:
received: 12 08 2021
revised: 27 01 2022
accepted: 03 02 2022
pubmed: 15 4 2022
medline: 3 1 2023
entrez: 14 4 2022
Statut: ppublish

Résumé

The human gut microbiota is the microbial ecosystem in the small and large intestines of humans. It has been naturally preserved and evolved to play an important role in the function of the gastrointestinal tract and the physiology of its host, protecting from pathogen colonization, and participating in vitamin synthesis, the functions of the immune system, as well as glucose homeostasis and lipid metabolism, among others. Mounting evidence from animal and human studies indicates that the composition and metabolic profiles of the gut microbiota are linked to the pathogenesis of cardiovascular disease, particularly arterial hypertension, atherosclerosis, and heart failure. In this review article, we provide an overview of the function of the human gut microbiota, summarize, and critically address the evidence linking compositional and functional alterations of the gut microbiota with atherosclerosis and coronary artery disease and discuss the potential of strategies for therapeutically targeting the gut microbiota through various interventions.

Identifiants

pubmed: 35420126
pii: 6568455
doi: 10.1093/cvr/cvac057
doi:

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3171-3182

Subventions

Organisme : British Heart Foundation
ID : CH/F/21/90009
Pays : United Kingdom

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Déclaration de conflit d'intérêts

Conflict of interest: This manuscript was handled by Associate Editor Dominik N Müller.

Auteurs

Dimitris Tousoulis (D)

1st Cardiology Department, National and Kapodistrian University of Athens, Vas. Sofias Avenue 114, 11527 Athens, Greece.

Tomasz Guzik (T)

Institute of Cardiovascular Medical Sciences, BHF Glasgow Cardiovascular Research Centre, UK.

Teresa Padro (T)

Sant Pau Institute for Biomedical Research, Barcelona, Spain.

Dirk J Duncker (DJ)

Department of Cardiology, Thorax Center, Erasmus MC, Rotterdam, the Netherlands.

Giuseppe De Luca (G)

Division of Cardiology, Eastern Piedmont University, Novara, Italy.

Etto Eringa (E)

Institute of Cardiovascular Research, Amsterdam University Medical Center, Amsterdam, the Netherlands.

Marija Vavlukis (M)

University Ss. Cyril and Methodius, Skopje, North Macedonia.

Alexios S Antonopoulos (AS)

1st Cardiology Department, National and Kapodistrian University of Athens, Vas. Sofias Avenue 114, 11527 Athens, Greece.

Themistoklis Katsimichas (T)

1st Cardiology Department, National and Kapodistrian University of Athens, Vas. Sofias Avenue 114, 11527 Athens, Greece.

Edina Cenko (E)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Ana Djordjevic-Dikic (A)

University Clinical Center of Serbia, Belgrade, Serbia.

Ingrid Fleming (I)

Centre of Molecular Medicine, Goethe University, Frankfurt, Germany.

Olivia Manfrini (O)

Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

Danijela Trifunovic (D)

Cardiology Department, University of Belgrade, Belgrade, Serbia.

Charalambos Antoniades (C)

RDM Division of Cardiovascular Medicine, University of Oxford, Oxford, UK.

Filippo Crea (F)

Department of Cardiology and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH